NASDAQ · CALC
Healthcare · Biotechnology
$1.66
Up+$0.05 (+3.25%)
Updated Oct 29, 2026, 4:34 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CALC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 28, 2026
CALC closed at $1.66 after 21 trading sessions, up 2.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 28, 2026 | $1.40 | $1.67 | $1.355 | $1.66 | 211.5K |
| Oct 27, 2026 | $1.26 | $1.35 | $1.26 | $1.31 | 40.38K |
| Oct 26, 2026 | $1.26 | $1.50 | $1.25 | $1.30 | 157.99K |
| Oct 23, 2026 | $1.19 | $1.3499 | $1.16 | $1.23 | 107.97K |
| Oct 22, 2026 | $1.26 | $1.31 | $1.13 | $1.15 | 123.36K |
| Oct 21, 2026 | $1.10 | $1.20 | $1.07 | $1.15 | 143.65K |
| Oct 20, 2026 | $1.03 | $1.10 | $1.02 | $1.065 | 42.84K |
| Oct 19, 2026 | $1.03 | $1.0832 | $1.00 | $1.02 | 18.09K |
| Oct 16, 2026 | $1.05 | $1.215 | $1.04 | $1.04 | 13.5K |
| Oct 15, 2026 | $1.08 | $1.152 | $1.05 | $1.08 | 22.59K |
| Oct 14, 2026 | $1.10 | $1.20 | $1.03 | $1.07 | 41.96K |
| Oct 13, 2026 | $1.22 | $1.23 | $1.085 | $1.12 | 98.86K |
| Oct 12, 2026 | $1.27 | $1.275 | $1.19 | $1.205 | 74.9K |
| Oct 9, 2026 | $1.2991 | $1.34 | $1.27 | $1.27 | 82.15K |
| Oct 8, 2026 | $1.46 | $1.50 | $1.30 | $1.30 | 221.62K |
| Oct 7, 2026 | $1.485 | $1.49 | $1.46 | $1.48 | 8.17K |
| Oct 6, 2026 | $1.53 | $1.61 | $1.42 | $1.49 | 169.11K |
| Oct 5, 2026 | $1.625 | $1.625 | $1.53 | $1.54 | 26.63K |
| Oct 2, 2026 | $1.64 | $1.70 | $1.58 | $1.60 | 21.83K |
| Oct 1, 2026 | $1.62 | $1.7094 | $1.60 | $1.65 | 25.93K |
| Sep 30, 2026 | $1.67 | $1.67 | $1.60 | $1.62 | 38.66K |
The latest Smart Investors Daily articles mentioning CALC.
Company
Market Activity
Research & News
CALC research
Company profile and research snapshot.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Guggenheim | Buy | — |
| Mar 5, 2026 | Oppenheimer | Outperform | — |
| Jan 29, 2026 | HC Wainwright & Co. | Neutral | — |
| May 15, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 16, 2026
On October 15, 2026, Stephen Bardin, the Chief Financial Officer, principal accounting officer and principal financial officer of CalciMedica, Inc. (the "Company"), provided notice of his resignation, to be
Benzinga · Sep 30, 2026
https://www.sec.gov/Archives/edgar/data/1534133/000119312526409041/d145394d424b5.htm
Benzinga · Sep 16, 2026
-SEC Filing
Yahoo · Sep 8, 2026
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CALC.
